Organon Reports Q1 Revenue Decline and Adjusted EPS Drop Amidst Pending Acquisition
Summary
Organon & Co. reported a 4% decline in Q1 revenue and a 30% drop in adjusted diluted EPS, with no future guidance provided due to its pending $13 billion acquisition by Sun Pharmaceutical.
Key Events
-
Q1 Revenue Decline
Organon reported Q1 2026 revenue of $1.460 billion, a 4% decrease as-reported and a 9% decline excluding foreign currency impacts, compared to Q1 2025.
-
Adjusted EPS Drop
Non-GAAP Adjusted diluted earnings per share fell 30% to $0.71 in Q1 2026 from $1.02 in Q1 2025.
-
Women's Health Weakness
The Women's Health segment saw a 16% as-reported revenue decline, primarily due to decreased Nexplanon sales and market contraction in China for oral contraceptives.
-
Biosimilars Growth
The Biosimilars segment was a bright spot, with revenue increasing 23% as-reported, driven by strong Hadlima performance and contributions from new assets.
Analysis
This filing provides Organon's first-quarter financial results, revealing significant operational headwinds with a 4% revenue decline and a 30% decrease in adjusted diluted EPS. The Women's Health segment, a core area, experienced a notable 16% revenue drop. While the Biosimilars segment showed strong growth, it was insufficient to offset broader declines. These results come shortly after the company announced a definitive merger agreement to be acquired by Sun Pharmaceutical for $13 billion. The company has ceased providing financial guidance and will not host earnings calls, which is customary during a pending acquisition. Investors should note these operational challenges as the company transitions towards its acquisition, providing a final look at its standalone performance.
At the time of this filing, OGN was trading at $13.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $5.69 to $13.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.